Back to Search
Start Over
Preclinical Characterization of an ANTI-CD38/CD3 T CELL-Redirecting Bispecific Antibody
- Source :
- Blood; November 2019, Vol. 134 Issue: 1, Number 1 Supplement 1 p4463-4463, 1p
- Publication Year :
- 2019
-
Abstract
- Introduction:Multiple Myeloma (MM) and Non-Hodgkin Lymphoma (NHL) are hematologic malignancies that remain difficult to treat. While autologous CAR-T cell therapies have shown promise in treating these diseases, these therapies are not without issues, including lack of response in many patients, lengthy time to produce CAR-T cells, occasional production failures, as well as high manufacturing costs. As an alternative approach, protein-based T cell engaging and redirecting bispecific antibodies (BsAbs) have been developed. We have generated anti-CD38/CD3 BsAbs to redirect T cells against CD38, a clinically validated antigen in MM and studied their ability to elicit target-dependent tumor cell lysis. The lead molecule is a humanized, stability-engineered CD3-engaging and CD38 antigen affinity-optimized BsAb with reduced effector function to mitigate antigen-independent T cell toxicity. Preclinical data demonstrate potent anti-tumor activity in vitroassays and in vivostudies against CD38-expressing lymphoma and MM cell lines.
Details
- Language :
- English
- ISSN :
- 00064971 and 15280020
- Volume :
- 134
- Issue :
- 1, Number 1 Supplement 1
- Database :
- Supplemental Index
- Journal :
- Blood
- Publication Type :
- Periodical
- Accession number :
- ejs56877926
- Full Text :
- https://doi.org/10.1182/blood-2019-131540